GlassScriptPhysician profile
Diego F Ferro
NPI 1700027877
$1,714.95
in general payments reported to CMS, 2019-2025
15 companies · $509 in 2025
The $509 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $259 · 2021: $18.73 · 2022: $155 · 2023: $213 · 2024: $255 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $976.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $732.40 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $233.10 | 2019-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $152.13 | 2022-2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $121.83 | 2025 | |
| Corcept Therapeutics | $115.00 | 2024 | Korlym |
| Janssen Pharmaceuticals, INC | $104.51 | 2019-2023 | Xarelto |
| Amgen INC. | $77.13 | 2022-2025 | Repatha, Otezla, Repatha |
| Dexcom, INC. | $30.42 | 2024 | Dexcom G6 Transmitter |
| Ironwood Pharmaceuticals, INC | $30.38 | 2019-2024 | |
| Astellas Pharma US INC | $24.35 | 2024 | Veozah |
| Allergan, INC. | $22.56 | 2019 | |
| Abbott Laboratories | $19.68 | 2025 | Freestyle Libre 3 |
| Pfizer INC. | $18.73 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.69 | 2025 | |
| Horizon Therapeutics Plc | $15.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Ferro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.